Definium Therapeutics: Phase 3 data paves the way for a $13.2 billion market - Bank of America sees around 130% price potential

Definium Therapeutics (DFTX) focuses on psychedelic-based medications for brain disorders, thereby addressing structurally growing treatment markets. The recent Phase 3 study Panorama on DT120 for generalized anxiety disorder achieved its primary endpoints and strengthens the company's approval perspective. Bank of America raises the price target to $91 and forecasts industry-leading peak revenues of up to $13.2 billion. Focus on psychedelic-based therapies for global health markets The business model of the clinical biopharmaceutical company...